Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Personen
Suche
EN
Alle Personen
Simona Sacco
Sortiert nach Typ
Datum
Vorsitz
08.12.2023
08:30
–
09:30
Debate session
DS 2 | Epidemiology: Migraine is more frequent in women – myth or fact?
Plenary hall
Invited speaker
Invited lecture
Epidemiology of headache in children and adolescents: A new pandemia?
Vortrag
ePoster
P036
Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
Weitere Beteiligungen
ePoster
P036
Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P021
Predictors of ≥50% and ≥75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
ePoster
P060
Effectiveness and tolerability of CGRP monoclonal antibodies in combination with monoclonal antibodies for other diseases: a multicenter study
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
ePoster
P106
Network meta-analysis of atogepant vs. CGRP mAbs on migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine
ePoster
P292
Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC) – preliminary results
ePoster
LP051
Reimbursement rules for CGRP mAbs throughout europe: an overview of the various constraints used
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz